Kyung Dong Pharmaceutical Co Ltd (011040) Stock Price & News

011040:KOSDAQ

Kyung Dong Pharmaceutical Co Ltd

₩5,020.00

-0.59%

(-30.00) 1D

Oct 20, 3:30:30 PM GMT+9 · KRW

All symbols

	Symbol	Price	Change	% Change

Generating top insights for 011040...

Open

₩5,050

High

₩5,050

Low

₩4,995

Mkt. cap

154.46B

Avg. vol.

124.32K

Volume

10.47K

Dividend

5.98%

Quarterly dividend

₩75

Ex-dividend date

Dec 29, 2025

P/E ratio

7.75

52-wk high

₩6,270

52-wk low

₩4,700

EPS

₩647

Shares outstanding

30.77M

No. of employees

332

Open

₩5,050

High

₩5,050

Low

₩4,995

Mkt. cap

154.46B

Avg. vol.

124.32K

Volume

10.47K

Dividend

5.98%

Quarterly dividend

₩75

Ex-dividend date

Dec 29, 2025

P/E ratio

7.75

52-wk high

₩6,270

52-wk low

₩4,700

EPS

₩647

Shares outstanding

30.77M

No. of employees

332

Related stocks

002800

Sinsin Pharmaceutical Co Ltd

₩4,265.00

-1.16%

007370

Jin Yang Pharmaceutical Co Ltd

₩3,835.00

-1.67%

006620

DongKoo Bio & Pharma Co Ltd

News stories

From web sources and news partners

FXStreet

1 hour ago

Nasdaq and S&P 500 hold key support – But is another sell-off coming? [Video]

شبكة تواصل الإخبارية

23 minutes ago

Dow Jones futures rise as markets bet on Fed rate hold, tech recovery | FXStreet

Investing.com

20 minutes ago

Wells Fargo issues buy signal for S&P 500 after sentiment shift

Yahoo Finance

2 hours ago

Should You Wait Until After the Midterm Elections to Buy the S&P 500?

About Kyung Dong Pharmaceutical Co Ltd

CEORyu Deok-Hee

Employees332

Founded1975

Headquarters-

SectorPharmaceutical industry

Websitekdpharma.co.kr

All values in KRW	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	48.88B	52.16B	47.81B	52.26B
Cost of goods sold	19.32B	21.72B	18.17B	19.79B
Cost of revenue	19.32B	21.72B	18.17B	19.79B
Research and development expenses	1.03B	2.48B	2.27B	2.55B
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	25.04B	24.95B	24.33B	25.71B
Operating expense	26.47B	27.88B	27.23B	28.77B
Total operating expenses	45.79B	49.59B	45.40B	48.56B
Operating income	3.09B	2.57B	2.41B	3.70B
Other non operating income	-9.54M	-275.41M	-525.56M	51.44M
EBT including unusual items	5.06B	3.38B	5.79B	7.01B
EBT excluding unusual items	3.17B	2.55B	3.66B	4.71B
Income tax expense	651.02M	545.55M	1.07B	1.25B
Effective tax rate	12.86%	16.12%	18.43%	17.86%
Other operating expenses	102.45M	125.84M	292.56M	156.19M
Net income	4.42B	2.89B	4.74B	5.78B
Net profit margin	9.04%	5.53%	9.92%	11.06%
Earnings per share	-	-	-	-
Interest and investment income	545.11M	569.79M	1.20B	322.29M
Interest expense	-454.94M	-411.90M	-430.01M	-420.06M
Net interest expenses	90.17M	157.89M	766.62M	-97.76M
Depreciation and amortization charges	211.15M	233.68M	226.64M	223.10M
EBITDA	4.03B	3.56B	3.43B	4.73B
Gain or loss from assets sale	-1.35B	-926.68M	-	-444.42M

Ask anything